In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer.
Purpose: To determine the safety and efficacy of in-bore magnetic resonance-guided prostate biopsy (MRGB) for detection of clinically significant disease (CSD) in untreated men with known or suspected prostate cancer (PCa). Methods: 512 patients underwent multiparametric magnetic resonance imaging (...
| Publicado en: | Abdominal Radiology Vol. 41; no. 5; pp. 954 - 963 |
|---|---|
| Autores principales: | , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
May2016
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=115423582&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 115423582 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 2366004X JT14 jtl: Abdominal Radiology issn: 2366004X maglogo: N pubinfo: dt: May2016 vid: 41 iid: 5 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 115423582 10.1007/s00261-016-0750-7 115423582 ppf: 954 ppct: 9 formats: fmt: @attributes: type: P tig: atl: In-bore magnetic resonance-guided transrectal biopsy for the detection of clinically significant prostate cancer. aug: au: Felker, Ely Lee-Felker, Stephanie Feller, John Margolis, Daniel Lu, David Princenthal, Robert May, Stuart Cohen, Martin Huang, Jiaoti Yoshida, Jeffrey Greenwood, Bernadette Kim, Hyun Raman, Steven affil: Department of Radiology, Ronald Reagan-UCLA Medical Center, 757 Westwood Plaza Suite 1638 Los Angeles 90095 USA sug: ab: Purpose: To determine the safety and efficacy of in-bore magnetic resonance-guided prostate biopsy (MRGB) for detection of clinically significant disease (CSD) in untreated men with known or suspected prostate cancer (PCa). Methods: 512 patients underwent multiparametric magnetic resonance imaging (Mp-MRI) followed by MRGB at one of three centers in this IRB-approved, HIPAA-compliant, retrospective study. Exclusion criteria were prior prostate cancer therapy and incomplete Mp-MRI ( n = 51). Patients ( n = 461) were analyzed in two subcohorts: no prior PCa (NP) ( n = 381) and active surveillance (AS) ( n = 80). Detection rates of PCa and CSD (Gleason Score ≥3 + 4) were calculated and compared among subcohorts and by Mp-MRI assessment grade. Logistic regression was performed to identify predictors for detection of PCa and CSD. Results: Mean patient age was 66 years, median prostate-specific antigen (PSA) was 7.5 ng/mL, and median prostate volume was 54 cc. A mean of 1.7 targets was sampled per gland. Significant adverse events (urosepsis and hematuria with obstruction) occurred in 1% (5/461). Overall PCa detection rates were 51% per patient (233/461) and 37% per lesion (282/757). 65% (151/233) of men with detected PCa had CSD. Per-patient PCa detection rates in the NP and AS subcohorts were 47% (178/381) and 69% (55/80), respectively, significantly higher in the AS group ( p < 0.001). CSD was detected in 10% (47/451), 43% (96/225) and 84% (68/81) of lesions with Mp-MRI assessment grades of 3, 4, and 5, respectively. Older age, higher PSA, and lower prostate volume predicted MRGB detection of CSD (OR 1.07 and p = 0.003, OR 1.1 and p = 0.014, and OR 0.98 and p = 0.032, respectively). Conclusions: In-bore MRGB is safe and high yield for detection of CSD. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|